Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025.

Fast Track designation is designed to expedite clinical development and regulatory review timelinesEnrolling patients in the GLEAM trial for ...

Sana Biotechnology (SANA) announced that the U.S. Food and Drug Administration granted Fast Track designation for SC291 in relapsed/refractory systemic lupus erythematosus, which includes extrarenal ...

The U.S. Food and Drug Administration gave SC291, a CD19-directed allogeneic CAR T cell therapy developed using Sana's hypoimmune platform, fast track designation, a process designed to facilitate the ...

Sana Biotechnology, Inc.'s stock has dropped, but with pipeline focus and upcoming trial data, its prospects remain mixed ...

Under plans to extend the company’s cash runway into 2026, Sana said it has halted development of its CD19-directed allogeneic CAR T-cell therapy, dubbed SC291, in cancer and will instead focus ...

Prioritize clinical and preclinical development on type 1 diabetes (UP421 and SC451), B-cell mediated autoimmune diseases (SC291), refractory B-cell malignancies (SC262), and the fusogen platform ...

Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships ...

Sana Biotechnology (NASDAQ:SANA) reported encouraging early data from a Phase 1 study for its CD19-directed allogeneic CAR T therapy called SC291 in the treatment of chronic lymphocytic leukemia ...

[Click here for information about joining the class action] On November 4, 2024, Sana issued a press release announcing that it "will suspend development of both SC291 in oncology and of SC379 ...